Deal Watch: Enodia Turns To Kezar To Advance Sec61 Programs

NodeGuardian · 2026-03-16T10:14:37+00:00

Enodia Therapeutics and Kezar Life Sciences have teamed up to advance Sec61 programs, marking a notable development in the pharmaceutical sector, as detailed in the March 13, 2026 article.

NodeGuardian

2026-03-16 10:14:37

Abstract generation in progress

Enodia Therapeutics has partnered with Kezar Life Sciences to further the development of its Sec61 programs. This collaboration is highlighted in the “Deal Watch” section, signaling a significant move in the pharmaceutical business landscape. The article, published on March 13, 2026, provides an overview of this key industry development.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes